Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 149,600 shares, a growth of 8.3% from the March 31st total of 138,100 shares. Currently, 1.1% of the company’s shares are short sold. Based on an […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were purchased at an average price of $3.86 per share, for a total transaction of $115,800.00. Following the completion of the transaction, the director now owns 30,000 […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were acquired at an average cost of $3.86 per share, for a total transaction of $115,800.00. Following the purchase, the director now directly owns 30,000 shares in […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 143,200 shares, a decline of 18.9% from the November 15th total of 176,500 shares. Based on an average daily trading volume, of 60,000 shares, the short-interest […]
Gain Therapeutics (NASDAQ:GANX – Free Report) had its price objective reduced by HC Wainwright from $10.00 to $9.00 in a research report report published on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2023 earnings at ($0.33) EPS, FY2023 earnings at […]